Back to Search
Start Over
Late-onset hypogonadism: a concept comes of age.
- Source :
-
Andrology [Andrology] 2020 Nov; Vol. 8 (6), pp. 1506-1511. Date of Electronic Publication: 2019 Nov 15. - Publication Year :
- 2020
-
Abstract
- The term Late-onset hypogonadism (LOH) was coined in 2002 and defined as a disease entity in the ISA, ISSAM, EAU, EAA and ASA endorsed Recommendations for Investigation, Treatment and Monitoring of LOH (2005 and 2008) as 'a clinical and biochemical syndrome associated with advancing age, characterized by symptoms and a deficiency in serum testosterone (T)'. LOH was classified as a combined primary and secondary hypogonadism since the endocrine capacity of the testes and the pituitary are impaired. Symptoms of LOH include loss of libido, erectile dysfunction, loss of muscle mass, increased body fat, anemia, osteoporosis, depressed mood, decreased vitality, sweating, and hot flushes. Since these symptoms may also have origins other than LOH, exclusion of other disease entities and subnormal serum T levels are considered prerequisites for the diagnosis and possible treatment of LOH. However, during following years these guidelines were often neglected and, especially in the USA, indiscriminate prescribing of T was widely practised so that the US FDA warned against such irresponsible behavior. In Europe, T prescribing remained largely restricted to LOH as defined above. Nevertheless, a discussion started whether LOH really exists or is only a consequence of age-related comorbidities. Numerous studies have helped to clarify the situation, in particular, the European Male Aging Study (EMAS) and the US-initiated 7 T trials. Consequently, the newest US Endocrine Society Practice Guideline on T treatment (2018) includes advanced age as a cause of organic hypogonadism and recommends that 'in men >65 years who have symptoms or conditions suggestive of T deficiency … and consistently and unequivocally low morning T concentrations we suggest that clinicians offer T therapy on an individualised basis after explicit discussion of the potential risks and benefits'. Thus, the concept of LOH as conceived two decades ago has weathered criticism and survived the times.<br /> (© 2019 American Society of Andrology and European Academy of Andrology.)
- Subjects :
- Age of Onset
Aged
Animals
Biomarkers blood
Clinical Decision-Making
Eunuchism blood
Eunuchism diagnosis
Eunuchism epidemiology
Humans
Male
Middle Aged
Risk Assessment
Risk Factors
Testosterone adverse effects
Testosterone blood
Testosterone deficiency
Treatment Outcome
Eunuchism drug therapy
Hormone Replacement Therapy adverse effects
Testosterone therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 2047-2927
- Volume :
- 8
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Andrology
- Publication Type :
- Academic Journal
- Accession number :
- 31639279
- Full Text :
- https://doi.org/10.1111/andr.12719